• Home
  • About Us
  • Blog

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Congenital Heart Disease
      • Eisenmenger’s Syndrome
      • Update on Management of PAH-CHD
      • Congenital Heart Disease & Sleep Apnea
      • Complex Congenital Heart Disease
      • Atrial Septal Defect and Pulmonary Arterial Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Porto-Pulmonary Syndrome
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Sotatercept (Winrevair) Approved
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Research
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH
    • FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH, Costs

Medicare: What You Need to Know

November 11, 2016 By Dr. Jeremy Feldman

PAH patient

With Medicare Open Enrollment currently underway (October 15th through December 7th) we thought this would be a good time to review some basic facts about Medicare. So if you have chronic lung disease like Pulmonary Arterial Hypertension or Pulmonary Fibrosis, here's what you need to know. What is Medicare? Medicare is the federal health insurance program for people 65 and … [Read more...]

How Will I Afford My PAH Medications?

October 27, 2016 By Dr. Jeremy Feldman

pulmonary hypertension medications

The cost of Pulmonary Arterial Hypertension medications is staggering.  The least expensive medication  (generic sildenafil) costs $50 per month for 90 tablets.  If you prefer to have the branded version and you don’t have any insurance expect to pay more than $3,000 per month.  Insurance companies are very happy to pay for generic sildenafil but increasingly restrict Adcirca … [Read more...]

Pulmonary Hypertension Association Registry (PHAR)

October 24, 2016 By Dr. Jeremy Feldman

PAH research

A registry is a recording of patients and their characteristics.  The PHAR is the first attempt by the PHA to begin to characterize and keep track of PH patients.  This ambitious undertaking hopes to be able to identify best practices for the care of PH patients.  As the registry matures we will be able to ask scientific questions and test hypotheses.  It represents the first … [Read more...]

Everyone Says I Look Great

October 21, 2016 By Dr. Jeremy Feldman

How You Look vs. How You Feel with Pulmonary Hypertension You can’t always judge a book by its cover.  Some medical problems are obvious and others are not so obvious.  One of the challenges of PAH is that for many patients their disease is not evident to the casual observer.  My patients are frustrated that their friends and family often comment that they look great even when … [Read more...]

Flu Vaccine in Young Adults with Congenital Heart Disease and Pulmonary Hypertension

October 14, 2016 By Dr. Jeremy Feldman

PH Support Group

By Tabitha Moe and Jeremy Feldman As a young adult with congenital heart disease, it is important for you to take responsibility for your own health and well being.  Over the years your parents and caregivers may have made decisions for you.  As a young adult, you now are in a position to make your own decisions about your health and wellness. We are approaching flu season, … [Read more...]

« Previous Page
Next Page »

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

Pulmonary hypertension medication list

How to complete a medication list

By Dr. Jeremy Feldman

Treating pulmonary hypertension requires several different types of medications.  Your physician may use diuretics,

Insurance Authorizations for PAH

Prior Authorization for PH Medications

By Dr. Jeremy Feldman

Medications used to treat pulmonary arterial hypertension are expensive.  Most insurance companies require a prior

good news in pah

 

Disclaimer

Recent Blog Posts

  • Making Order from Chaos October 26, 2025
  • Sotatercept: ZENITH and HYPERION Trials June 22, 2025
  • In Memoriam:  Greg Ahearn, MD June 16, 2024

Categories

Archives